Skip to main content
. Author manuscript; available in PMC: 2022 Apr 15.
Published in final edited form as: Int J Cardiol. 2020 Dec 24;329:123–129. doi: 10.1016/j.ijcard.2020.12.048

Table 2.

In-hospital tests, procedures, and treatment of HF QUIK participants by control and intervention period.

Diagnostic tests and treatment Control (n = 758)1 Intervention (n = 642)1 P-value

In-hospital tests and procedures
ECG, No. (%) 751 (99.1) 641 (99.8) 0.06
Cardioversion, No. (%) 23 (3.0) 14 (2.2) 0.32
Stress testing, No. (%) 1 (0.1) 0 (0.0) 0.36
Coronary angiography, No. (%) 163 (21.5) 133 (20.7) 0.72
Percutaneous coronary intervention, No. (%) 45 (5.9) 44 (6.9) 0.48
Coronary artery bypass graft, No. (%) 6 (0.8) 9 (1.4) 0.27
Implantable cardioverter defibrillator, No. (%) 4 (0.5) 3 (0.5) 0.87
Cardiac resynchronization therapy, No. (%) 1 (0.1) 3 (0.5) 0.24
Intra-aortic balloon pump, No. (%) 0 (0.0) 1 (0.2) 0.28
Dialysis or ultrafiltration, No. (%) 8 (1.1) 9 (1.4) 0.56
Non-invasive positive pressure ventilation, No. (%) 218 (28.8) 173 (26.9) 0.45
Mechanical ventilation, No. (%) 68 (9.0) 57 (8.9) 0.95
In-hospital treatment
Loop diuretic, No. (%) 713 (94.1) 631 (98.3) <0.001
Thiazide diuretic, No. (%) 16 (2.1) 16 (2.5) 0.63
ACE-I or ARB, No. (%) 310 (40.9) 283 (44.1) 0.23
Beta-blocker, No. (%) 542 (71.5) 478 (74.5) 0.22
Aldosterone antagonist, No. (%) 436 (57.5) 431 (67.1) <0.001
ARNi, No. (%) 17 (2.2) 8 (1.2) 0.16
Digoxin No. (%) 153 (20.2) 107 (16.7) 0.09
Ivabradine, No. (%) 78 (10.3) 70 (10.9) 0.71
Aspirin, No. (%) 632 (83.4) 556 (86.6) 0.09
Statin, No. (%) 638 (84.2) 559 (87.1) 0.12
Hydralazine-nitrate, No. (%) 45 (5.9) 23 (3.6) 0.04
Nitroglycerin, No. (%) 219 (28.9) 204 (31.8) 0.24
Inotrope, No. (%) 129 (17.0) 126 (19.6) 0.21

ECG: electrocardiogram, ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, ARNi: angiotensin receptor neprilysin inhibitor

1

Data were completely reported for all variables in Table 2.